Jeffrey L. Brown

发表

Anti‐tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells

Y. Bang, A. Lau, M. O’Connor, 2017, International journal of cancer.

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models

Jeffrey L. Brown, T. Bihani, G. Hattersley, 2017, Clinical Cancer Research.

Angiogenesis , Metastasis , and the Cellular Microenvironment Inhibition of the Hedgehog Pathway Targets the Tumor-Associated Stroma in Pancreatic Cancer

R. Hwang, Jeffrey L. Brown, T. Moore, 2012 .

The KNH1 gene of Saccharomyces cerevisiae is a functional homolog of KRE9

H. Bussey, Howard Bussey, Jeffrey L. Brown, 1996, Yeast.

A new family of yeast genes implicated in ergosterol synthesis is related to the human oxysterol binding protein

H. Bussey, J. Sheraton, N. Fortin, 1994, Yeast.

Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

L. Naldini, Jeffrey L. Brown, Michele De Palma, 2011, Cancer cell.

Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

K. Webster, Zhong-ying Liu, Jeffrey L. Brown, 2009, Molecular Cancer Therapeutics.

Clinical Molecular Diagnostics for Proteasome Inhibitors in Cancer Therapy

G. Ginsburg, G. Mulligan, J. Stec, 2004 .

The selective Trk inhibitor AZ623 inhibits brain‐derived neurotrophic factor–mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan

Jeffrey L. Brown, P. Zage, K. Thress, 2011, Cancer.

Therapeutic targeting of Trk supresses tumor proliferation and enhances cisplatin activity in HNSCC

J. Myers, Jeffrey L. Brown, T. Jiffar, 2010, Cancer biology & therapy.

Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway

T. Stankovic, A. Lau, Jeffrey L. Brown, 2015, The Lancet.

Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action

Chris P. Miller, Jeffrey L. Brown, Suqin He, 2017, Clinical Cancer Research.

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Mohammad Tabrizi, Steve Emery, Corinne Reimer, 2010, Molecular Cancer Therapeutics.

AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts

Jeffrey L. Brown, R. Ho, J. Minturn, 2012, Cancer Chemotherapy and Pharmacology.

Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.

H. Sasaki, Jeffrey L. Brown, S. Moriyama, 2014, Molecular and clinical oncology.

The Yeast KRE9 Gene Encodes an 0 Glycoprotein Involved in Cell Surface ,-Glucan Assembly

H. Bussey, Jeffrey L. Brown, Jeffrey L. Brown, 1993 .

Glycosyl Phosphatidylinositol-dependent Cross-linking of ct-Agglutinin and /1,6-Glucan in the Saccharomyces cerevisiae Cell Wall

H. Bussey, F. Klis, Jeffrey L. Brown, 2002 .

Molecular Cancer Therapeutics A Human Monoclonal Anti-ANG 2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Jeffrey L. Brown, Z. Cao, M. Pinzon-Ortiz, 2009 .

Chemotherapy Agents in Preclinical Models Antitumor Activity in Combination with VEGF Inhibitors and A Human Monoclonal Anti-ANG 2 Antibody Leads to Broad

Jeffrey L. Brown, Z. Cao, M. Pinzon-Ortiz, 2009 .

Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition

Daria M. Tanska, T. Lawrence, J. Maybaum, 2011, Clinical Cancer Research.

SKN7, a yeast multicopy suppressor of a mutation affecting cell wall beta-glucan assembly, encodes a product with domains homologous to prokaryotic two-component regulators and to heat shock transcription factors

H. Bussey, S. North, J. Brown, 1993, Journal of bacteriology.

Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

K. Webster, Zhong-ying Liu, P. Zage, 2009, Molecular Cancer Therapeutics.